Findings from the First-in-Human Phase 1 Trials of NX-2127 and NX-5948, Bruton’s Tyrosine Kinase (BTK) Degraders, in Patients with Relapsed/Refractory B Cell Malignancies

Time: 9:00 am
day: Conference Day Two


  • Observe how the activity demonstrated by the BTK degraders, NX-2127 and NX-5948 in phase 1 clinical trials, provide proof of concept for clinical potential of targeted protein degradation
  • Understand that all BTK degraders are not created equally
  • Learn how BTK degradation overcomes mutational liabilities associated with BTK inhibitors